IDEA AG
10
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
40%
4 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)
Role: lead
Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee
Role: lead
Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness
Role: lead
A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee
Role: lead
Effect of IDEA-070 on Pain and Inflammation Induced by PDT
Role: lead
IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA
Role: lead
Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee
Role: lead
Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise
Role: lead
An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee
Role: lead
IDEA-033 Open Label Study
Role: lead
All 10 trials loaded